Success Metrics

Clinical Success Rate

93.5%

Based on 87 completed trials

Completion Rate

94%(87/93)

Active Trials

7(6%)

Results Posted

43%(37 trials)

Terminated

6(5%)

Phase Distribution

Ph early_phase_1

Ph phase_2

26%

Ph phase_3

19%

Ph phase_4

17%

Ph not_applicable

23%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution117 total trials

Early Phase 1First-in-human

3(2.6%)

Phase 1Safety & dosage

15(12.8%)

Phase 2Efficacy & side effects

30(25.6%)

Phase 3Large-scale testing

22(18.8%)

Phase 4Post-market surveillance

20(17.1%)

N/ANon-phased studies

27(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.9%

87 of 99 finished

Non-Completion Rate

12.1%

12 ended early

Currently Active

trials recruiting

Total Trials

117

all time

Status Distribution

Active(12)

Completed(87)

Terminated(12)

Other(6)

Detailed Status

Completed87

Withdrawn6

Terminated6

Recruiting6

Not yet recruiting5

unknown5

Development Timeline

Analytics

Development Status

Total Trials

117

Active

Success Rate

93.5%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (2.6%)

Phase 115 (12.8%)

Phase 230 (25.6%)

Phase 322 (18.8%)

Phase 420 (17.1%)

N/A27 (23.1%)

Trials by Status

active_not_recruiting11%

withdrawn65%

terminated65%

completed8774%

recruiting65%

not_yet_recruiting54%

unknown54%

suspended11%

Recent Activity

7 active trials

Showing 5 of 117

completednot_applicable

Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults

NCT07706361

terminatedphase_4

Lidocaine Patches in Elderly Patients With Traumatic Rib Fractures

NCT05714631

View all 117 trials

Clinical Trials (117)

Showing 20 of 117 trialsScroll for more

NCT07731230Not Applicable

Biomodulator Patch for Subjective Tinnitus

Completed

NCT03973229Early Phase 1

Neuroendocrine Risk for PTSD in Women

Completed

NCT02162849Phase 4

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Active Not Recruiting

NCT07706361Not Applicable

Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults

Not Yet Recruiting

NCT05714631Phase 4

Lidocaine Patches in Elderly Patients With Traumatic Rib Fractures

Terminated

NCT07671612Not Applicable

PBM Patch for Postoperative Pain Relief After Urological Surgery

Not Yet Recruiting

NCT06798571Phase 4

Role of Menopause in Thermoregulation

Recruiting

NCT06460350Not Applicable

NEUROCUPLE™ in TKA Patients to Enhance Pain Management

Completed

NCT05587361Phase 4

Beta-Adrenergic Modulation of Drug Cue Reactivity

Recruiting

NCT07353021Not Applicable

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

Not Yet Recruiting

NCT07330726Phase 3

Lidocaine Patch and Lower Third Molar

Not Yet Recruiting

NCT05412992Phase 2

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty

Terminated

NCT07083635Phase 2

Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users

Recruiting

NCT06866613Phase 3

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Completed

NCT02720445Phase 2

Memory Improvement Through Nicotine Dosing (MIND) Study

Completed

NCT04683627Phase 3

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Completed

NCT06455969Phase 4

Adaptions and Resiliency to Multi-Stressor OpeRations

Recruiting

NCT07081971Not Applicable

Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure

Not Yet Recruiting

NCT04366518Early Phase 1

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting

NCT03834363Phase 4

Morphine or Fentanyl for Refractory Dyspnea in COPD

Completed

Drug Details

Intervention Type: DEVICE
Total Trials: 117